REG - Renalytix PLC - Three kidneyintelX.dkd Clinical Integrations

RenalytixAnnouncement

12/01/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260112:nRSL4881Oa&default-theme=true

RNS Number : 4881O  Renalytix PLC  12 January 2026

Renalytix plc

("Renalytix" or the "Company")

 

Three kidneyintelX.dkd Clinical Integrations

 

LONDON and NEW YORK, 12 January 2026 - Renalytix plc (LSE: RENX) (OTCQB:
RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the
only FDA-approved and Medicare reimbursed prognostic test to support
early-stage risk assessment in chronic kidney disease, announces that during
the last quarter of 2025 it successfully completed three additional health
care provider clinical integrations in the United States. Initial testing
volumes have now commenced across all sites. The Company continues to expand
its electronic health care integrated testing with one-click ordering for ease
of physician use.

 

The integrations were completed with Joseph P. Addabbo Family Health Center in
New York, Central Florida Kidney Specialists in Florida and The Kidney Experts
PLLC in Tennessee. All three sites are established regional kidney care
providers and the integrations were implemented directly by Renalytix.

 

These integrations enable the use of Renalytix's kidney disease testing
solutions within each practice's existing clinical workflow. While each
practice currently represents modest initial testing volumes, the Company
anticipates growing utilisation over time as adoption expands across their
respective patient populations.

 

Renalytix continues to focus on disciplined expansion of its clinical
footprint and expects to complete additional integrations with healthcare
providers in early calendar year 2026. The Company believes this measured
approach supports scalable growth in test utilisation, while maintaining
efficient deployment of internal resources.

 

Tempus AI Collaboration

 

Renalytix continues to work closely with Tempus AI, Inc. ("Tempus") to advance
electronic health record integrated testing and data collection with major US
healthcare providers in alignment with its longer-term goal of data-driven
kidney disease solutions. Personnel from Tempus and Renalytix has been working
closely together since this key collaboration was announced in September 2025
(https://www.londonstockexchange.com/news-article/RENX/tempus-ai-inc-collaboration-agreement/17230023)
, to target the healthcare customers integrated with Tempus that have large,
costly populations of diabetes and kidney disease patients.

 

The collaboration with Tempus will support the development of solutions to
enable future expansion into additional clinical and geographic markets over
time.

 

Investor Engagement

 

James McCullough, Chief Executive Officer, is attending the J.P. Morgan
Healthcare Conference in the US this week, where Renalytix will engage with
existing and prospective investors and stakeholders as part of its ongoing
corporate development and investor relations programmes.

 

The 44(th) annual conference is the largest healthcare investment symposium
in the industry, which connects global industry leaders, emerging fast growth
companies, innovative technology creators and members of the investment
community from the USA and the wider international investment community. The
conference is attended by a broad range of healthcare and life sciences
companies, including data and diagnostics partners such as Tempus.

 

The Company looks forward to updating investors on progress, corporate
development and trading in February 2026.

 

For further information, please contact:

 

 Renalytix plc                                         www.renalytix.com (http://www.renalytix.com)
 James McCullough, CEO                                 Via Walbrook PR

 SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)             Tel: +44 (0)20 3470 0470
 Jeff Keating / David Hignell (Corporate Finance)

 Vadim Alexandre (Corporate Broking)

 Oberon Capital (Joint Broker)                         Tel: +44 (0)20 3179 5300
 Mike Seabrook / Nick Lovering

 Walbrook PR Limited        Tel: +44 (0)20 7933 8780 or renalytix@walbrookpr.com
                            (mailto:renalytix@walbrookpr.com)
 Paul McManus / Alice Woodings                         Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

About Renalytix (www.renalytix.com)

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in
vitro diagnostics company, focused on optimizing clinical management of kidney
disease to drive improved patient outcomes. Renalytix has received FDA
approval and Medicare reimbursement for kidneyintelX.dkd which is now offered
commercially in the United States.

 

Unrecognized and uncontrolled kidney disease remains one of the largest
barriers to controlling cost and suffering in the United States and the United
Kingdom's medical system, affecting approximately 15 million and 8 million
people, respectively. After five years of development and clinical validation,
kidneyintelX.dkd is the only FDA-approved and Medicare reimbursed prognostic
tool capable of understanding a patient's risk with kidney disease early where
treatment has maximal effect. kidneyintelX.dkd is now being deployed across
large physician group practices and health systems in select regions of the
United States.

 

The over 15,000 patients that have been tested by kidneyintelX.dkd have
produced a substantial body of real-world performance data. In patient
populations where kidneyintelX.dkd has been deployed, a demonstrated and
significant increase in diagnosis, prognosis, and treatment rates have been
recorded. kidneyintelX.dkd now has full reimbursement established by Medicare,
the largest insurance payer in the United States, at $950 per reportable
result. kidneyintelX.dkd is also recommended for use in the international
chronic kidney disease clinical guidelines (KDIGO).

 

KidneyIntelX is based on technology developed by Mount Sinai faculty and
licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and
equity owners in the Company. In addition, the Icahn School of Medicine at
Mount Sinai has equity ownership in Renalytix. For information about the
kidneyintelX,dkd test, visit kidneyintelx.com (http://kidneyintelx.com/) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCKZGMMLMNGVZM



            Copyright 2019 Regulatory News Service, all rights reserved